BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

282 related articles for article (PubMed ID: 21067536)

  • 1. Antiangiogenic therapy for breast cancer.
    Nielsen DL; Andersson M; Andersen JL; Kamby C
    Breast Cancer Res; 2010; 12(5):209. PubMed ID: 21067536
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeting angiogenesis in esophagogastric adenocarcinoma.
    Okines AF; Reynolds AR; Cunningham D
    Oncologist; 2011; 16(6):844-58. PubMed ID: 21632459
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Anti-angiogenic therapy: concept to clinic.
    Young RJ; Reed MW
    Microcirculation; 2012 Feb; 19(2):115-25. PubMed ID: 22078005
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeting angiogenesis in metastatic breast cancer.
    Reddy S; Raffin M; Kaklamani V
    Oncologist; 2012; 17(8):1014-26. PubMed ID: 22843553
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical experience with antiangiogenic therapy in leukemia.
    Wellbrock J; Fiedler W
    Curr Cancer Drug Targets; 2011 Nov; 11(9):1053-68. PubMed ID: 21999626
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Novelties in the treatment for advanced renal-cell cancer].
    Maráz A
    Orv Hetil; 2011 Apr; 152(17):655-62. PubMed ID: 21464023
    [TBL] [Abstract][Full Text] [Related]  

  • 7. VEGF inhibition and metastasis: possible implications for antiangiogenic therapy.
    English BC; Price DK; Figg WD
    Cancer Biol Ther; 2009 Jul; 8(13):1214-25. PubMed ID: 19483467
    [No Abstract]   [Full Text] [Related]  

  • 8. The role of antiangiogenesis therapy: bevacizumab and beyond.
    Cortés-Funes H
    Clin Transl Oncol; 2009 Jun; 11(6):349-55. PubMed ID: 19531449
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Drug insight: VEGF as a therapeutic target for breast cancer.
    Schneider BP; Sledge GW
    Nat Clin Pract Oncol; 2007 Mar; 4(3):181-9. PubMed ID: 17327858
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Emerging data with antiangiogenic therapies in early and advanced non-small-cell lung cancer.
    Horn L; Sandler AB
    Clin Lung Cancer; 2009 Mar; 10 Suppl 1(Suppl 1):S7-16. PubMed ID: 19362948
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Role of anti-angiogenesis agents in treating NSCLC: focus on bevacizumab and VEGFR tyrosine kinase inhibitors.
    Cabebe E; Wakelee H
    Curr Treat Options Oncol; 2007 Feb; 8(1):15-27. PubMed ID: 17634832
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeted therapy in advanced non-small-cell lung cancer.
    Gettinger S
    Semin Respir Crit Care Med; 2008 Jun; 29(3):291-301. PubMed ID: 18506667
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sunitinib, sorafenib and mTOR inhibitors in renal cancer.
    Radulovic S; Bjelogrlic SK
    J BUON; 2007 Sep; 12 Suppl 1():S151-62. PubMed ID: 17935273
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Angiogenesis inhibition: review of the activity of sorafenib, sunitinib and bevacizumab].
    Barrascout E; Medioni J; Scotte F; Ayllon J; Mejean A; Cuenod CA; Tartour E; Elaidi R; Oudard S
    Bull Cancer; 2010; 97():29-43. PubMed ID: 20418202
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hemangiopericytoma and antiangiogenic therapy: clinical benefit of antiangiogenic therapy (sorafenib and sunitinib) in relapsed malignant haemangioperyctoma /solitary fibrous tumour.
    Domont J; Massard C; Lassau N; Armand JP; Le Cesne A; Soria JC
    Invest New Drugs; 2010 Apr; 28(2):199-202. PubMed ID: 19352594
    [No Abstract]   [Full Text] [Related]  

  • 16. [The role of angiogenesis in renal carcinoma].
    Bussolati B; Satolli MA; Camussi G
    G Ital Nefrol; 2008; 25(3):297-305. PubMed ID: 18473301
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Renal cell carcinoma and antiangiogenic therapies].
    Pouessel D; Culine S; Verhoest G; Patard JJ
    Presse Med; 2008 Apr; 37(4 Pt 2):628-33. PubMed ID: 18035517
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Molecular biology of renal cell carcinoma.
    Mellado B; Gascón P
    Clin Transl Oncol; 2006 Oct; 8(10):706-10. PubMed ID: 17074668
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Angiogenesis targeting in renal carcinomas].
    Pouessel D; Culine S
    Bull Cancer; 2007; 94(7 Suppl):F223-6. PubMed ID: 17965000
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Antiangionic drugs in soft tissue sarcoma].
    Salas S; Huynh T; Deville JL; Duffaud F
    Bull Cancer; 2010 Jun; 97(6):701-5. PubMed ID: 20483703
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.